Method for treating a perioheral arterial disease
US-2024425576-A1 · Dec 26, 2024 · US
Methods of administering D-dopachrome tautomerase (D-DT) to treat ischemia-reperfusion injury
US9308255B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9308255-B2 |
| Application number | US-201113989182-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 23, 2011 |
| Priority date | Nov 24, 2010 |
| Publication date | Apr 12, 2016 |
| Grant date | Apr 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the discovery that reduced levels of D-dopachrome tautomerase (D-DT) (also known as MIF-2) are associated with ischemia-reperfusion injury. Thus, the present invention relates to methods of administering D-DT and recombinant D-DT for the treatment of ischemia-reperfusion injury.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating or reducing ischemia-reperfusion injury in a subject, or a tissue or an organ thereof, the method comprising: administering to the subject, the tissue, or the organ thereof, a therapeutically effective amount of a composition comprising at least one selected from the group consisting of a D-dopachrome tautomerase (D-DT) polypeptide, and a recombinant D-DT polypeptide. 2. The method of claim 1 , wherein the composition is administered to a tissue or an organ, and wherein the tissue or the organ is at least one selected from the group consisting of heart, kidney, liver and brain. 3. The method of claim 2 , wherein the composition is administered to the tissue or the organ in vivo. 4. The method of claim 2 , wherein the composition is administered to the tissue or the organ in vitro. 5. The method of claim 1 , wherein the subject, tissue or organ is human. 6. The method of claim 1 , wherein the D-DT polypeptide or recombinant D-DT polypeptide is human D-DT polypeptide or human recombinant D-DT polypeptide.
Assignees
Inventors
Classifications
Single chain antibody (scFv) · CPC title
- C07K16/24Primary
against cytokines, lymphokines or interferons · CPC title
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
- A61K39/3955Primary
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Peptides of undefined number of amino acids; Derivatives thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9308255B2 cover?
- The present invention relates to the discovery that reduced levels of D-dopachrome tautomerase (D-DT) (also known as MIF-2) are associated with ischemia-reperfusion injury. Thus, the present invention relates to methods of administering D-DT and recombinant D-DT for the treatment of ischemia-reperfusion injury.
- Who is the assignee on this patent?
- Bucala Richard J, Young Lawrence H, Univ Yale
- What technology area does this patent fall under?
- Primary CPC classification C07K16/24. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).